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Summary 
Altering ubiquitination by disruption of individual deubiquitinating enzymes (DUBs) has proven 
to affect hematopoietic stem cell (HSC) maintenance. However, comprehensive knowledge of 
DUB function during hematopoiesis in vivo is lacking. To accomplish this goal, we 
systematically inactivated DUBs in mouse hematopoietic progenitors using in vivo small hairpin 
RNAs (shRNAs) screens. We found that multiple DUBs may be individually required for 
hematopoiesis and that the ubiquitin-specific protease 15 (USP15) is particularly important for 
the maintenance of murine hematopoietic stem and progenitor cells in vitro and in vivo. 
Consistently, Usp15 knockout mice exhibited a reduced HSC pool. The defect was intrinsic to 
HSCs, as demonstrated by competitive repopulation assays. Importantly, USP15 is highly 
expressed in normal human hematopoietic cells and leukemias, and USP15 depletion in murine 
early progenitors and myeloid leukemia cells impaired in vitro expansion and increased 
genotoxic stress. Our study underscores the importance of DUBs in preserving normal 
hematopoiesis and uncovers USP15 as a critical DUB in safeguarding genome integrity in HSC 
and in leukemia cells. 
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Introduction 
Mammalian hematopoiesis depends on a limited pool of stem cells in the bone marrow. 
Hematopoietic stem cells (HSCs) have the unique properties of self-renewal and multi-lineage 
potential, giving rise to daughter stem cells and to committed progenitors, thereby achieving 
lifelong hematopoiesis. This is accomplished by careful maintenance of a homeostatic balance 
between HSC quiescence, self-renewal and differentiation (de Haan and Lazare, 2018; Laurenti 
and Gottgens, 2018; Morrison and Spradling, 2008). Perturbation of this balance as well as 
replication stress can cause stem cell failure or transform normal HSCs and progenitors into 
disease-initiating leukemic stem cells (LSCs) (Flach et al., 2014; Warr et al., 2011). 
Understanding HSC and bone marrow homeostasis is therefore essential for understanding 
mechanisms controlling diseases and ultimately for targeting LSCs (Warr et al., 2011).  
  The 76 amino-acid molecule ubiquitin is conjugated to proteins as a monomer (mono-
ubiquitination) or in the form of ubiquitin-chains (poly-ubiquitination) through the sequential 
action of E1 ubiquitin activating-, E2 ubiquitin conjugating- and E3 ubiquitin ligating-enzymes 
(Yau and Rape, 2016). Deubiquitinating enzymes (DUBs; also referred to as deubiquitylating 
enzymes or deubiquitinases) reverse substrate ubiquitination. By removing or editing the 
ubiquitin chains from their targets, DUBs critically regulate ubiquitin-mediated signaling 
pathways, including protein homeostasis, DNA repair and receptor signaling (Clague et al., 
2012; Mevissen and Komander, 2017). Consequently, deregulation of DUBs is implicated in 
human pathologies, such as cancer, neurodegenerative and hematological and infectious diseases 
(Heideker and Wertz, 2015).  
  The human genome encodes ≈100 DUBs, grouped in seven families based on structural 
properties. Four of these DUB families belong to the cysteine proteases [ubiquitin-specific 
proteases (USPs), ovarian tumor proteases (OTUs), ubiquitin C-terminal hydrolases (UCHs) and 
Josephin domain DUBs], one is the motif interacting with ubiquitin (MIU)- containing novel 
DUB family [MINDYs], one consists of the JAMM/MPN+ family of metalloproteases, and the 
seventh is represented by the recently identified ZUFSP (Haahr et al., 2018; Kwasna et al., 2018; 
Mevissen and Komander, 2017). By a mouse genetic approach our laboratory reported that loss 
of the ubiquitin-specific protease 3 (USP3) protects the HSCs from functional decline through 
modulation of ubiquitin-dependent DNA damage response (DDR), a critical genome 
maintenance pathway (Lancini et al., 2014). This is in line with a proper DDR being crucial to 
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HSC function (Bakker and Passegue, 2013; Biechonski et al., 2017). Notably, numerous DUBs 
control ubiquitin-dependent DDR signaling (Citterio, 2015; Jackson and Durocher, 2013; Nishi 
et al., 2014; Schwertman et al., 2016) and recent studies provided evidence that DUBs 
deregulation contributes to altered HSC homeostasis and human blood diseases, including 
myelodysplastic syndrome (MDS) (Adorno et al., 2013; Dey et al., 2012; Gu et al., 2016; 
Higuchi et al., 2016; Nakagawa et al., 2015), with some of the DUBs primarily impacting on 
DDR (Citterio, 2015; Lancini et al., 2014; Parmar et al., 2010).  
  Functional analysis of HSC within their physiological environment is more likely to 
result in finding modulators potentially relevant in disease (Morrison and Spradling, 2008; 
Schepers et al., 2015). Unbiased, functional genomic approaches by short hairpin RNAs 
(shRNAs) have demonstrated the power of forward RNAi screens in dissecting functional 
aspects of both normal (Cellot et al., 2013; Galeev et al., 2016; Hope et al., 2010) and leukemic 
HSCs (Zuber et al., 2011). Using lentiviral-based libraries frequently employed in cancer gene 
discovery (Gargiulo et al., 2014), pooled in vivo screening approaches in early murine 
hematopoietic precursors led to the identification of critical factors limiting normal HSC self-
renewal under DNA damage conditions (Sertorio et al., 2017; Wang et al., 2012) as well as of 
determinants of malignant hematopoiesis (Miller et al., 2013; Puram et al., 2016).  
While recent gene-centric approaches connected DUBs to HSC maintenance (Adorno et 
al., 2013; Dey et al., 2012; Gu et al., 2016; Higuchi et al., 2016; Lancini et al., 2014; Nakagawa 
et al., 2015; Nijnik et al., 2012; Parmar et al., 2010; Wang et al., 2013), a comprehensive 
understanding of DUBs biological functions in hematopoiesis and leukemia is missing. DUBs 
are poorly represented in in vivo published screens (Sertorio et al., 2017; Wang et al., 2012) and 
in vitro functional approaches for DUBs in cancer cell lines were hypothesis driven (Nishi et al., 
2014). In this study, we individually depleted all DUB genes using in vivo RNAi screens in 
mouse hematopoietic precursors, with the aim of ranking the most relevant DUBs required for 
normal and malignant hematopoiesis. From this systematic and targeted approach, we uncovered 
novel and known DUBs as putative regulators of hematopoietic precursors activity and 
highlighted USP15 as a novel determinant of hematopoiesis in vivo and its role in preserving 
genome integrity, with potential implications for combinatorial treatments in leukaemia.  
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Results 
In vivo RNAi screens for deubiquitinating enzymes (DUBs) identify known and novel 
regulators of hematopoietic stem and progenitor cell activity 
To identify DUB determinants of mouse HSC activity, we performed pooled in vivo RNAi 
screens using adult murine hematopoietic stem and progenitor cells in a bone marrow (BM) 
transplantation setting (Fig. 1A). To this end, we generated a custom pool of 508 lentiviral 
shRNAs vectors potentially targeting all annotated mouse orthologues of human DUBs (≈100) 
(Mevissen and Komander, 2017). This primary library contained 3 to 6 shRNA vectors per gene, 
selected from the shRNA library developed by the RNAi Consortium (TRC) at the Broad 
Institute (Open Biosystem) (Table S1, S2). Since the statistical representation of shRNA libraries 
is critical for success in in vivo screening, we used the full library in a primary screen, and 
divided the library in two sub-pools (DUB1 and DUB2 sub-libraries), subsequently used in 
secondary screens (Fig. 1B). To perform qualitative controls, we included in each library 
shRNAs targeting known HSCs regulators as positive controls (Park et al., 2003; Vasanthakumar 
et al., 2016; Wang et al., 2012). 
Freshly isolated Lineage negative (Lin-) BM cells were transduced with the titered 
shRNAs pooled library (MOI<<1), selected with puromycin and subsequently injected into 
lethally irradiated mice (Fig. 1A). In this limited time window, Lin- cells were maintained in 
vitro in the presence of HSC cytokines, in conditions that are known to preserve and enrich for 
stem cells/early progenitors (Materials and Methods)(Ye et al., 2008). Indeed, early progenitors 
were maintained during transduction, as gauged by the enrichment of the Lin-cKit+Sca1+ (LSK) 
cells in FACS analysis (Fig. S1A). Notably, the transduced cell culture also retained phenotypic 
HSCs, which was assessed by the HSC SLAM surface marker CD150+ that is expressed on cells 
endowed with an immature phenotype and reconstitution potential (Christensen and Weissman, 
2001; Kiel et al., 2005; Yeung and Wai Eric So, 2009) (Fig. S1A). Transduced Lin- cells were 
mixed 1:1 with total BM cells from CD45.1 mice, which is the state of art for competitive in vivo 
transplantation (Fig. 1A). To ensure optimal representation of the shRNA library, we have 
injected a minimum of 1x106 Lin- transduced cells/mouse, aiming at least at a predicted 2000-
fold library representation per animal. This representation is estimated to be sufficient to control 
for grafting efficiency and stochastic drifts (Gargiulo et al., 2014). 
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We allowed cells to engraft recipient animals and harvested blood, BM and spleen from recipient 
mice at 4 weeks post transplantation (wpt). We chose a 4-week time-point as read-out of the 
screen based on experimentally determined parameters. First, we verified that 4 weeks is a 
sufficiently long time to allow the assessment of potential phenotypic defects of the murine 
progenitors during the acute proliferative phase. This included both expansion and depletion, 
thereby enabling us to identify genes regulating either quiescence or proliferation. Second, 4 
weeks is a time-frame consistent with polyclonal engraftment and insufficient to allow 
manifestation of compensatory mechanisms and HSC clonality issues. In fact, in long-term 
engraftment experiments (4- 6 months), only a small number of HSC contribute to most cellular 
output (Naik et al., 2013). In our experiments, we observed measurable grafting in recipients 
and the generation of donor-derived B cells in the spleen of transplanted recipients (Fig. S1). 
This supports the 4-weeks time-point as being sufficient to enable the screen while limiting HSC 
clonal expansion. 
 FACS analysis of BM, circulating blood cells and splenocytes showed successful 
engraftment of the transduced Lin- cells, with an average of 50% contribution as measured in the 
BM (Fig. 1C, Fig. S1B and S1C). To assess the relative representation of each shRNA in vivo, we 
then performed parallel next generation sequencing of PCR-amplified shRNA sequences from 
genomic DNA in the following conditions: 1) in vivo hematopoietic precursors and differentiated 
cells, isolated at 4 wpt from the BM (Lin- cells) or the spleen (CD43-, CD45.2+, CD19+, 
CD220+ B cells), respectively, of recipients, 2) controls: transduced Lin- cells immediately before 
injection (INPUT, T0) as well as the plasmid library. Sequencing of individual samples revealed 
that individual shRNA abundance in transduced Lin- (T0) correlated well with the hairpin reads 
in the plasmid library, supporting efficient transduction in vitro (R2=0.69, Fig. S2A). Importantly, 
more than 97% of the hairpins could be identified in the transduced Lin- (T0) and more than 89% 
were retrieved in vivo in purified Lin- cells from each recipient mouse (4 wpt). We concluded that 
a significant proportion of the initial library complexity is maintained in vitro and in vivo, 
respectively (Fig. S2A and Fig. 1D).  
Principal component analysis (PCA) showed that the five in vivo BM samples were more 
similar to each other and were distinct from the input cells before injection, and limited variance 
between the individual samples was found (Fig. S2B, C). Moreover, a positive correlation was 
found between the relative representation of shRNAs retrieved from the BM to the ones retrieved 
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from the spleen (R2=0.668), thereby supporting an overall good quality of the primary screen 
(Fig. S2D and Table S3).  
Next, we performed a differential enrichment analyses on the in vivo and control samples. 
Overall, the behavior of well-known HSC regulators enhanced confidence in our in vivo RNAi 
screen. In fact, among the top hits we found genes relevant to HSC biology to be either enriched 
(involved in cell cycle restriction) or depleted (supporting self-renewal), including our positive 
controls. Consistent with the requirement for Bmi1 in adult HSC self-renewal (Park et al., 2003), 
two out of the 4 shRNAs targeting Bmi1 showed significant dropout (> 20 fold) in Lin- cells in 
vivo (Fig. 1E, Table S3). DNA repair genes BRCA1 and BRCA2/FANCD1 were also highly 
depleted with at least one shRNA per gene, in line with their crucial role in HSC survival 
(Navarro et al., 2006; Vasanthakumar et al., 2016). Consistent with a role in cell cycle restriction 
(Wang et al., 2012), two shRNAs for the cell cycle inhibitor Cdkn1a were enriched (Fig. 1E). 
Notably, DUBs with established importance in HSC maintenance, including USP1 (Parmar et al., 
2010), USP3 (Lancini et al., 2014) and USP16 (Adorno et al., 2013; Gu et al., 2016) also scored 
top hits from the primary screen, and were targeted by two independent shRNAs (Fig. 1F, Fig. 
S2H and Table S3). These data further demonstrate the ability of our unbiased in vivo screen to 
identify DUBs relevant to HSC biology.  
To validate our primary screen and increase its statistical power, we divided the primary 
library in two, mostly non-overlapping, shRNA sub-pools (DUB1 and DUB2 sub-library) and 
performed secondary screens under similar transplantation conditions (Fig. 1B, 1F and Fig. 
S1C). In line with the primary screen, high hairpins representation in vitro and in vivo (>95%), 
low variance between individual mice and the performance of positive control shRNAs support 
the overall quality and reproducibility of the secondary screens as well (Fig. 1F, G, Fig. S2E-G, 
and Table S3). Although many shRNAs showed similar changes in representation in the primary 
and in the secondary screens, a measurable variation was also present. This is likely due to 
inconsistencies in transduction efficiency or to the stochastic gain or loss of shRNAs following 
in vivo growth (Table S3). To overcome this, we adopted stringent selection parameters. We 
considered as candidates for follow up analyses those genes for which at least two shRNAs were 
depleted/enriched by 10-fold median in the BM relative to their representation in the T0 control 
(i.e. the injected cell population; Adj.Pvalue ≤0.02) in each screen, and which were called as hits 
in at least two independent experiments. When multiple hairpins showed opposite effect, the 
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corresponding gene was excluded. By these criteria, our positive controls as well as 14 out of 81 
DUB genes tested were validated in the secondary screens and were defined as positive hits (Fig. 
1F, Fig. S2H).  
To prioritize hits for follow up, we next focused on DUBs with reported high expression 
in LSK and in HSC (Cabezas-Wallscheid et al., 2014; Heng et al., 2008; Lancini et al., 2016) 
(immgen.org). We choose to focus on USP15, for which three independent shRNAs were 
depleted for >15-fold median in the bone marrow after 4 weeks, and the top scoring shRNAs 
showed a 60-fold dropout (Fig. 1E and G, Table S3). We and others found that USP15 (Baker et 
al., 1999) is expressed in the early progenitor compartment (LSK) and in HSC (Cabezas-
Wallscheid et al., 2014; Lancini et al., 2016), as well as in blood and in splenic B cells (Lancini 
et al., 2016; Vlasschaert et al., 2017). Together with our screen results, these data suggest a 
potential role for USP15 in hematopoiesis, though no functional study in vivo has yet been 
reported. We therefore decided to further investigate the role of USP15 in HSC biology.  
 
USP15 depletion impairs hematopoietic stem and progenitor cells proliferation in vitro 
To investigate whether a role for USP15 in hematopoietic progenitors self-renewal is 
plausible, we first checked USP15 expression levels in the normal hematopoietic developmental 
tree by surveying published gene expression data sets. In the mouse bone marrow, Usp15 
expression is consistently high at single cell level and expression is homogeneous in the entire 
hematopoietic tree, being expressed at similar level in single mouse LT-HSCs and early lineage-
committed progenitors (Fig. S2I, J) (Nestorowa et al., 2016; Olsson et al., 2016). Importantly, 
Usp15 expression pattern in the mouse is similarly conserved in humans, as inferred by USP15 
expression in CD34+ human HSC as well as in early lineage-committed progenitors at single cell 
level (Fig. S2K) (Pellin et al., 2019). 
We therefore addressed the impact of individual USP15-targeting shRNAs on 
hematopoietic progenitors in vitro and in vivo (Fig. 2A). We first assessed the ability of the 
single shRNAs to reduce Usp15 expression upon low multiplicity of infection (MOI<<1), similar 
to the transduction conditions used in the RNAi screens. To cope with paucity of Lin- cells, we 
chose RT-qPCR as readout for knockdown efficiency. All three shRNAs identified in the 
secondary DUB screen (DUB2 sub-library; Fig. 1G, Table S3) downregulated USP15 expression 
in freshly isolated, lentiviral-infected Lin- cells (Fig. 2B). To functionally validate the two top-
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scoring lentiviral shRNA vectors in the screen, Lin- cells were transduced with either a control 
(shScramble) or USP15-targeting #sh16 and #sh17 shRNAs. To determine the effect of USP15 
depletion on the LSK compartment, the transduced cells were propagated in a serum-free 
medium supplemented with pro-self-renewal growth factors and analyzed by flow cytometry for 
the presence of LSK surface receptors at one-week post infection (8 days from initial culture). 
Within the Lin-, c-Kit+ population, the fraction of LSKs, representing the undifferentiated 
compartment capable of in vivo repopulation, remained comparable between the USP15-depleted 
and the control shRNA cells (Fig. 2C, left panel). Nevertheless, the expansion of both Lin-, c-
Kit+ and of LSK cells was affected by USP15 depletion compared to control shRNA (Fig. 2C, 
middle and right panels and Fig. S3A). Consistently, USP15 knockdown progenitors exhibited 
limited proliferation (Fig. 2D). Altogether, these data show that in vitro reduced expression of 
USP15 affects the proliferative ability of hematopoietic progenitors. 
 
USP15 depletion impairs stem and progenitor cells reconstitution potential in vivo 
To assess the effect of USP15 knockdown in a physiological setting, we transduced murine Lin- 
progenitors with USP15-targeting or control shRNAs and competitively co-transplanted these 
CD45.2 USP15-depleted or control progenitors together with freshly isolated CD45.1 BM cells 
(1:1 ratio) into lethally irradiated recipients. Chimerism in the blood was monitored over time. 
Within a period of 18 weeks, USP15 knockdown Lin- cells failed to contribute to a chimerism 
level beyond the 20% of total peripheral blood cells, whereas the chimerism level of control mice 
progressively increased, reaching the expected approximate 50% contribution (Fig. 3A). This 
underscores a competitive disadvantage of USP15 depleted cells compared to control shRNA-
transduced cells. At 18 wpt, we found that all lineages within CD45.2 USP15-depleted peripheral 
blood cells, including myeloid/granulocytes (CD11b+, GR1+ cells), B and T cells were equally 
affected as compared to their control counterpart (Fig. 3B and Fig. S3B). Similarly, USP15 loss 
affected multi-lineage reconstitution (B and T cells) of recipient animals’ spleen at 18 wpt, with 
an average 52% of control B cells compared to 25% and to 10.8% of USP15-#sh16 and USP15-
#sh17 cells respectively (Fig. 3C and Fig. S3C). 
The above results suggest a defect in the multilineage reconstitution potential of USP15 
depleted progenitors. Given that BM resident HSCs are mainly responsible to give rise to and 
maintain all blood cell lineages (Kiel et al., 2005; Wilson et al., 2008), we next quantified the 
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numbers of CD45.2+ cells in the BM of recipient mice transplanted with either USP15-depleted 
or control progenitors (Fig. S3D). To assess stem cell reconstitution, we chose 18 wpt as time-
point for BM immuno-phenotypical analysis, a time which is sufficient for essentially all mature 
hematopoietic cells to be derived from the most undifferentiated HSC (Naik et al., 2013). In line 
with the overall lower relative contribution to blood reconstitution (Fig. 3A), we measured a 
defect in USP15-depleted BM precursors. In fact, USP15-depleted LSK were reduced in 
frequency and numbers (2.38 and 8-fold reduction, respectively) compared to control 
(shScramble) LSK, which reached 50% contribution to the recipient mice LSK compartment 
(Fig. 3D, E). To specifically focus on HSCs, we then employed the HSC surface receptors 
SLAM CD48 and CD150 markers (Cabezas-Wallscheid et al., 2014; Kiel et al., 2005; Oguro et 
al., 2013). We found a significant decline (3.25 fold) of CD42.2 HSCs (as defined by 
LSK/CD48-/CD150+) in the BM of animals reconstituted with USP15 depleted cells, compared 
to controls (Fig. 3F). These comparisons underscore a defect in long-term hematopoiesis caused 
by USP15 loss and a critical role for USP15 in HSC in vivo maintenance. 
We next investigated the more differentiated, proliferative LKS- progenitors. USP15 
depletion resulted in a consistent decrease in donor-derived cells also in this compartment. A 
similar reduction of USP15-depleted cells compared to controls was measured in both the 
myeloid subsets of common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors 
(GMPs) and in the megakaryocyte-erythrocyte progenitors (MEPs) (Fig. 3G and Fig. S3D) 
(Yeung and Wai Eric So, 2009), confirming an important role for USP15 in preserving all the 
main hematopoietic differentiation pathways. 
In summary, in vivo phenotypic profiling supports a role for USP15 in preserving 
hematopoietic progenitor engraftment and multi-lineage reconstitution potential, which is needed 
for peripheral blood repopulation and distal hematopoiesis.  
 
USP15 knockout compromises normal HSC function in vivo  
To assess the role of USP15 in physiological hematopoiesis, we generated mice deficient 
for USP15 by germline genetic ablation using the CRISPR-Cas9 technology (Pritchard et al., 
2017) (Fig. S4A). Deletion of the Usp15 locus was achieved by co-injection of gRNAs and Cas9 
mRNA into the pronuclei of mouse zygotes and confirmed by PCR genotyping and Western blot 
(Fig. S4B, C). Homozygous USP15 knockout mice were viable, indicating that USP15 is 
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dispensable for embryonic development. However, initial characterization revealed that Usp15-/- 
animals were born at sub-Mendelian ratio and showed reduced survival when compared to 
Usp15+/+ mice, confirming a critical role for USP15 in vivo (Fig. S4D, E).  Decreased life span 
in Usp15-/- animals compared to wt littermates is accompanied by lower body weight (Fig. S4F). 
Interestingly, some of the Usp15 KO animals showed evidence of inflammatory lesions (Fig. 
S4G, H, and Table S7).  
We next screened young adult Usp15+/+ and Usp15-/- littermates (8-14 wks) for BM 
cellularity. No marked differences were found, suggesting that USP15 deficient BM can develop 
to a large extent normally (Fig. S4I). In line with this, phenotypic analysis revealed a normal 
frequency in the Lin-, cKit+ population in Usp15-/- and control mice (Fig. 4A, D), with a modest 
(but not significant) reduction in the Usp15-/- more undifferentiated stem and progenitors, the 
LSKs (Fig. 4B, D). Notably, within LSKs, the frequency and numbers of immature precursors 
endowed with reconstitution potential (LSK, CD135-, CD150+) (Christensen and Weissman, 
2001; Kiel et al., 2005; Yeung and Wai Eric So, 2009)(Fig. S4J-L) and, more specifically, of 
phenotypic HSC (LSK, CD48-, CD150+) (Cabezas-Wallscheid et al., 2014; Kiel et al., 2005; 
Oguro et al., 2013) (Fig. 4C, D) were significantly lower in knockout mice, reaching only 60% 
of their aged-matched wt controls. The more committed (myeloid) progenitor pools did not show 
any measurable phenotype, indicating that this compartment can functionally cope with a 
reduction of HSC at young adult age (Fig. S4M). Consistently, Usp15-/- BM cells performed 
similar to wt BM when assayed in vitro in myeloid colony formation assays (CFU-C) (Fig. S4N). 
In summary, during physiological hematopoiesis, USP15 loss particularly impacted on the HSC 
compartment, indicating that the maintenance of the more primitive HSC in adult mice depends 
on USP15 in vivo.  
  HSC are endowed with long-term multi-lineage reconstitution ability (Kiel et al., 2005). 
To establish whether the HSCs remaining in Usp15 knockout mice are functionally equivalent to 
those in wt littermates, we performed competitive BM transplantations. Upon transplantation of 
BM cells containing a 1:1 mixture of test and competitor cells (Methods), chimerism of CD45.2 
Usp15-/- peripheral blood cells in recipients significantly decreased over time compared to mice 
transplanted with Usp15+/+ BM (Fig. 5A). Usp15+/+ chimerism remained constant throughout 
the 18 weeks of analysis and reached the expected plateau. Importantly, USP15 deletion 
critically affected myeloid/granulocytes (CD11b+/Gr1+) as well as lymphoid blood cells 
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(CD19+ B cells and CD3+T cells) (Fig. 5B). This phenotype recapitulates the USP15 
knockdown defects observed upon transplantation of shRNA-transduced Lin- cells (Fig. 3A, B). 
In recipient BM at 18 wpt, a time shown to be sufficient for essentially all mature hematopoietic 
cells to be derived from the most undifferentiated HSC (Naik et al., 2013), we found 
significantly lower numbers of Usp15-/- LSKs as well as HSCs (LSK, CD150+, CD48-) 
compared to wt controls, suggesting that USP15-deficient HSCs have reduced self-renewal 
capacity into recipients compared to wt HSCs (Fig. 5C, D). Consequently, also the more 
committed Usp15-/- LKS- and CMP pools were diminished (Fig. 5E).  
We next examined the consequences of USP15 deletion on HSPC cellular homeostasis. 
By DAPI/immuno-phenotyping combined analysis of freshly isolated BM cells, we measured 
that Usp15-/- mice have similar numbers of quiescent HSPCs compared to wt mice. The majority 
of HSCs were in the G0/G1 phase of the cell cycle. Under these physiological conditions, no 
subsets of the HSPCs nor the HSC differed significantly in terms of percentage of cells in S/G2 
(Fig. S4O). Of note, freshly isolated Usp15-/- stem and progenitor cells did not show apparent 
apoptosis (Fig. S5P). Also, cleaved-caspase 3-positive cells were not readily detected on BM 
tissue sections of Usp15-/- mice (Fig. S4Q). RNA-seq of WT and Usp15-/- LSK confirmed the 
loss of Usp15 and the maintenance of an overall stable identity of the cellular compartment (Fig. 
S4R).  
Having established a functional defect in Usp15-/- LSK upon transplantation, we next 
assayed their intrinsic proliferative capacity in conditions of cytokine-induced replication. By 
monitoring the cell numbers of FACS sorted LSK in in vitro liquid cultures under stem cell 
conditions (Materials and Methods), we observed a significantly reduced intrinsic proliferative 
capacity for Usp15-/- LSKs compared to wt, which was exacerbated upon ex vivo culturing (Fig. 
5F).  
In all, systemic knockout validated USP15 as a novel positive regulator of HSC 
maintenance in vivo and proliferative capacity ex vivo. 
 
USP15 is highly expressed in human leukemia  
Leukemic stem cells (LSCs) share functional properties with normal HSCs. For instance, 
acute Myeloid leukemia (AML) and Chronic Myeloid leukemia (CML) arise in the early 
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hematopoietic compartment and have LSCs endowed with self-renewal and ability to propagate 
the disease (Kreso and Dick, 2014; Warr et al., 2011).  
Consistent with this, USP15 featured the highest of expression in human hematopoietic 
tissues and related cancers, including leukemia and lymphomas (The Cancer Genome Atlas, 
TCGA)(Fig. 6A-B). In a AML-specific dataset, USP15 expression was significantly higher in 
patients with AML carrying various genetic abnormalities compared to the normal human 
CD34+ -enriched BM hematopoietic precursors (Fig. 6C) (Bagger et al., 2013) (Hemaexplorer; 
www.bloodspot.eu). Of note, high expression of USP15 is statistically associated with tissue-
independent poor survival within the PANCANCER patient cohort, a feature generally 
associated with oncogenes (Fig. 6D and Table S8). 
To test whether these data are reflected in human cancer models, we next analyzed 
USP15 expression in the large panel of comprehensively characterized Cancer Cell Line 
Encyclopedia (CCLE). In line with the previous analyses, the highest expression was found in 
leukemia cell lines, including multiple AML and CML cell lines, compared to all other tissues 
(Fig. 6E). To experimentally validate these analyses, we profiled USP15 expression in a twenty-
three leukemia cell lines panel, including all maturation stages and chemotherapy resistant CML 
lines. With the sole exception of the KG1/KG1a cell line, USP15 mRNA was high in all the 
tested lines and independent from the leukemia stage. Interestingly, K562 and KBM7 blast crisis 
lines have very high USP15 expression (Fig. 6F). 
To test whether USP15 gene expression correlates with its genetic dependency, we 
ranked the dependency scores calculated by Demeter2 for USP15 RNAi in CCLE lines 
(McFarland et al., 2018). According to DepMap (https://depmap.org), USP15 expression and 
dependency varied across cell lines but were not linearly correlated, nor leukemia cell lines were 
specifically sensitive compared to other cancers (Fig. S5A). Next, we investigated whether 
cancer-related biological pathways activation would be informative as a biomarker for USP15 
dependency. To this end, we compiled a list of cell lines in which sensitivity to USP15 depletion 
was experimentally tested and could be classified as relatively high by DEMETER2 score (D2 
score <-0.2) or low (D2 score >0.2). Among the leukemia cell lines, MV-4-11 and Kasumi-1 
featured highly sensitive and SEM and K562 featured as less sensitive cell lines (Fig. S5A). 
Using PROGENy (Schubert et al., 2018), differential pathway activation between cell lines with 
varying degrees of sensitivity indicate that several RTK, JAK/STAT and PI3K signaling 
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pathways tend to anti-correlate with sensitivity to USP15 depletion, whereas VEGFA, HIF1A 
and TGF-beta signaling were found more active in highly sensitive cell lines (Fig. S5B). Across 
the whole spectrum of CCLE cell lines, however, there was no evident biomarker for response, 
except a trend for activation of the Trail pathway (Fig. S5C), suggesting that USP15 depletion 
may operate in context dependent manner. To experimentally address the potential impact of the 
regulation of these pathways in response to USP15 depletion, we next performed RNAi of 
USP15 on highly expressing KBM7 and K562 CML cell lines. K562 are considered as a low 
sensitive cell line within the DepMap dataset and therefore response to USP15 RNAi may be 
uncoupled from survival. Ingenuity pathway analysis identified 657 and 330 differentially 
regulated genes in KBM7 and K562, respectively. In line with PROGENy analysis, RNAi of 
USP15 led to activation of inflammation-related pathways, which involve JAK/STAT and PI3K 
signal transduction (Fig. S5D-G). In K562, we also measured significant down-modulation of 
TGF-beta signaling (Fig. S5H, I), which is required for USP15 pro-oncogenic role in human 
glioma cells (Eichhorn et al., 2012). 
Overall, these analyses indicate that USP15 is highly expressed in human primary 
leukemias and leukemia cell lines and that a subset of leukemia cells with various molecular 
alterations may be sensitive to USP15 loss.   
 
USP15 loss leads to genome instability in leukemia cell lines and in mice 
Given the context-dependent responses to USP15 depletion in CML cells and that 
reversal of ubiquitination often contributes to fine-tuning of the DNA damage response (DDR) 
(Nishi et al., 2014), we next focused on exploring a potential role for USP15 in genome 
maintenance. 
USP15 depletion by USP15-targeting siRNAs mildly but reproducibly reduced the 
viability of both “less sensitive” K562 and KBM7 and “more sensitive” MV411 and Kasumi-1 
cell lines (Fig. 7A, B, S5A and below). Despite the predicted low sensitivity to USP15 depletion, 
USP15 loss was accompanied by significant increase in the number of spontaneous nuclear foci 
of the DNA damage response factor 53BP1 as well as increase in the basal levels of γ-H2AX 
DNA damage marker and in the frequency of micronuclei in both K562 and KBM7 (Fig. 7C-F), 
all indicative of enhanced genotoxic stress. This mirrors the increase in micronucleation, as well 
as bi- and multinucleation and apoptotic/necrotic cells observed in FACS sorted LSKs from 
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the BM of Usp15 knockout mice upon culturing (Fig. 7G), thereby indicating that USP15 loss 
affects genome integrity in all of these settings. Spontaneous genotoxic stress was also observed 
in USP15 depleted osteosarcoma cells (Fig. S6A-H), thereby extending the validity of USP15 
expression as genome integrity safeguard mechanism to multiple tissue neoplasia. 
These data supported the hypothesis that USP15 depletion would render normal 
hematopoietic progenitors more sensitive to genotoxic stress in vivo. To test if this is the case, we 
injected mice with the chemotherapeutic agent cisplatin (0,8 mg/kg, a relative low dose 
compared to the 6mg/kg maximal tolerable dose used in C57BL6/6J mice (Pilzecker et al., 
2017)) i.v or with PBS, and analyzed the BM after 2 days. Upon cisplatin treatment, USP15 
knockout BM cells produced significantly fewer CFUs compared to wt (Fig. S6I), suggesting 
higher sensitivity of their HSPC compartment. Deeper BM analysis unmasked a broader 
sensitivity of the primitive progenitor compartment in Usp15-/- mice, including HSCs and LSKs, 
and also the more proliferative LKS-, myeloid (GMP) and lymphoid (CLP) progenitor 
populations to genotoxic stress (Fig. S6J, K). This effect may also be seen as an orthogonal 
validation of our results obtained upon transplantation-induced (replication) stress, overall 
suggesting that USP15 generally contributes to preserve the HSPCs compartment during stress-
induced hematopoiesis. 
Finally, we sought to translate these findings into a potential combination setting in 
leukemia. In leukemia cells originated by blast crisis such as KBM7 cells, we combined 
depletion of USP15 by dox-inducible RNAi and DNA single/double-strand breaks induction by 
ionizing radiation (IR).  USP15 depletion by a dox-inducible shRNA sensitized KBM7 cells to 
IR (Fig. 7H). A role for USP15 in supporting the DNA damage response was recently reported in 
breast cancer cells (Peng et al., 2019). In keeping with those findings, Rad51 protein levels were 
diminished by USP15 knockdown in MV411 and Kasumi-1 leukemia cells (Fig. S6L). A broader 
chemo-profiling in CCLE cancer cell lines indicated that leukemia cell lines are generally more 
sensitive than others to the DNA damage inducers Topotecan (Topoisomerase I inhibitor) and 
Mitomycin-C (a DNA cross-linking agent), two chemotherapeutic clastogenic agents (Fig. 7I). 
Notably USP15-depletion cooperated with Mitomycin-C to reduce cell viability in MV4-11 (Fig. 
7J).  
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.23.916627doi: bioRxiv preprint 
 17 
Overall, these data suggest that USP15 generally safeguards genome integrity in normal 
hematopoietic and leukemia cells and its loss affects survival in a selected subset of leukemia 
cells and sensitizes these cells to DNA damage inducers. 
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Discussion 
We report on the comprehensive assessment of the role for deubiquitinating enzymes in early 
hematopoiesis through the successful application of pooled in vivo shRNA screens in the mouse. 
Through focused in vivo RNAi screens, we have identified several genes within the family of 
DUBs whose loss increases or decreases mouse hematopoietic stem and progenitor cells fitness 
in vivo. Remarkably, in this unbiased approach, several known and novel DUBs were shown to 
regulate hematopoietic homeostasis. We followed upon USP15, which we characterized as a 
novel DUB required for early hematopoietic progenitor proliferation and for HSC homeostasis in 
vivo. Also, our findings uncover a conserved requirement for USP15 in preserving normal and 
leukemic stem cell genome integrity.  
Pooled in vivo screens in early progenitors pose specific technical challenges related to the 
heterogeneity of the starting population, the rare set of target stem and progenitor populations, 
the (long-term) grafting potential, and to selective pressure in vivo. The success of our shRNA 
screening approach is underscored by the successful shRNA library representation in Lin- cells, 
engraftment of transduced cells, detection of a large library representation in vivo in Lin- and in 
splenic B cells (≥90%) and retrieval of positive shRNAs controls in vivo.  Also, shRNAs 
targeting DUBs previously involved in HSC biology were scored in the screens, in particular 
USP1 (Parmar et al., 2010), USP3 (Lancini et al., 2014), USP16 (Adorno et al., 2013; Gu et al., 
2016) and BAP1 (Dey et al., 2012; Higuchi et al., 2016; Nakagawa et al., 2015; Nijnik et al., 
2012; Wang et al., 2013) (Table S3). Together with the extensive genetic validation, these 
examples raise confidence in the identification of USP15 as critical regulator of HSCs in vivo 
and validate the use of in vivo genetic screens for systematically characterizing the role of DUBs 
in tissue homeostasis. 
 Loss of USP15 in adult murine hematopoietic progenitors by RNAi or by germline 
deletion impaired their growth in vitro and repopulation ability in vivo. In USP15 knockout adult 
mice, HSC reserves in particular were significantly reduced, while more differentiated 
progenitors were largely maintained. These data suggest that chronic lack of USP15 likely allows 
for protective pathways/adaptation that ensure hematopoiesis at steady state and are consistent 
with a role for USP15 in contributing to homeostasis through the maintenance of HSCs, which 
are largely quiescent (Bakker and Passegue, 2013). HSC regenerative potential is, in fact, critical 
when HSC are induced into proliferation during ex-vivo culturing, (competitive) transplantation 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.23.916627doi: bioRxiv preprint 
 19 
(Flach et al., 2014; Walter et al., 2015), or upon aging (Beerman et al., 2010; de Haan and 
Lazare, 2018).  
We report that spontaneous genotoxic stress and enhanced sensitivity to clastogenic 
agents accompanied the decrease in viability of USP15 deficient hematopoietic progenitors and 
leukemia cells in vitro and of mouse primitive hematopoietic progenitors in vivo. These data link 
USP15 to the DDR and are consistent with previous work in cancer cell lines (Fielding et al., 
2018; Mu et al., 2007; Nishi et al., 2014; Peng et al., 2019). Although a genome maintenance 
defect may contribute to loss of fitness of USP15 deficient HSCs, understanding how USP15 
modulates the damage response and how its loss precisely impacts on HSC and cancer cells 
maintenance will require deep molecular characterization, not least through the identification of 
context-specific interactors. This endeavor may be facilitated by the current development of 
single-cell proteomics approaches. 
USP15 gene alterations have been found in cancer, in particular glioblastoma, breast, 
ovarian and recently in non-small cell lung cancer (Eichhorn et al., 2012; Fielding et al., 2018; 
Padmanabhan et al., 2018; Peng et al., 2019), as well as copy number losses in pancreatic cancer 
(Srihari and Ragan, 2013). Here, the analysis of cancer databases uncovers USP15 highest 
expression in primary blood-derived tumors and alterations in leukemia patients, particularly 
CML and AML. This is the first study to provide functional ground for investigating the role for 
USP15 as gatekeeper in leukemia. Our in vitro assays support targeting USP15 to suppress 
viability of a subset of leukemia cell lines, including cell lines derived from blast crisis stage 
CML, a stem-cell derived disease (Arrigoni et al., 2018). In both normal and tumor cells, USP15 
inhibition is accompanied by chromosomal aberrations indicating a susceptibility to DNA 
damage. Further research is needed to examine the role of USP15 in human HSC and the impact 
of USP15 loss of function or inhibition on steady-state human hematopoiesis. 
USP15 in involved in multiple cellular processes, including p53 (Liu et al., 2017; Zou et 
al., 2014) and NF-kB (Schweitzer et al., 2007) signaling, histone H2B deubiquitination (Long et 
al., 2014), and the transforming growth factor-β (TGF-β) pathway (Eichhorn et al., 2012; Inui et 
al., 2011; Iyengar et al., 2015), and showed interaction with a number of ubiquitin linkages in 
vitro (Zhang et al., 2017). Interestingly, recent studies have linked USP15 to inflammation in 
experimental models, through the regulation of type I and type II interferon (IFN) responses 
(Pauli et al., 2014; Torre et al., 2017; Zou et al., 2014; Zou et al., 2015). Also, by diminishing 
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TGF-β signaling, depletion of USP15 was shown to reduce the proliferation and the oncogenic 
capacity of patient-derived glioma-initiating cells (Eichhorn et al., 2012). TGF-β regulatory 
mechanisms and inflammatory signals are relevant both in normal HSC and in malignant 
development (Blank and Karlsson, 2015). Notably, upon USP15 knockdown in CML lines, we 
find significant changes in gene expression including up-regulation of genes associated with 
inflammation and down-regulation of TGF-beta signaling genes, suggesting that USP15 role in 
these cells may involve alterations in these pathways. While our data in leukemia cell lines 
indicate that context-specific pathways are likely to be affected by loss of USP15 in cancer cells, 
notably TGF-beta and inflammatory pathways, the limited changes in gene expression detected 
in LSK cells of the USP15 knockout mice suggests that Usp15 function in preserving genome 
integrity is dominant in this compartment. This may open to potential cancer cell specific drug 
combinations, which would spare normal cells from side effects.  
The function of USP15 in development is still poorly characterized. Here, we 
demonstrate a requirement for USP15 in HSC maintenance. Our results also support a broader 
role of USP15 in mammalian development, as knockout of USP15 has clear impact on 
Mendelian transmission and on mouse lifespan. This finding is not obvious when compared 
against previous reports in a USP15 gene-trap model (Zou et al., 2014). In our study, germline 
deletion of the entire USP15 locus by CRISPR/Cas9 generates mice with a complete gene 
knockout, allowing the manifestation of the full phenotype at organismal level. Growth 
retardation observed in our USP15 knockout mice is, in fact, in line with recently reported 
findings in another CRISPR-Cas9 USP15 knockout mouse model (Peng et al., 2019). Our mouse 
model enriches the toolbox available to the quest for mechanisms underlying USP15 function in 
vivo.   
USP4, USP11 and USP15 are part of a closely related family of USPs (Al-Salihi et al., 
2012; Das et al., 2017; Eichhorn et al., 2012; Long et al., 2014; Nishi et al., 2014; Orthwein et 
al., 2015; Vlasschaert et al., 2015; Wijnhoven et al., 2015; Zhang et al., 2012; Zhou et al., 2017). 
They are all expressed in hematopoietic early progenitors (Cabezas-Wallscheid et al., 2014; 
Heng et al., 2008; Lancini et al., 2016), but none was previously linked to HSC activity. All three 
genes scored as hits in our screen, suggesting that besides USP15, its paralogues may contribute 
to HSC homeostasis and might functionally cooperate. Notably, USP15 deficiency in mice was 
suggested to be lethal when the mice were bred with USP4-targeted mice, suggesting partially 
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redundant roles in vivo (Vlasschaert et al., 2015). The discovery of USP15, USP11 and USP4 
individually as critical modulators of HSC homeostasis opens to the study of specific and 
redundant roles in a physiological setting. The potential redundancy and biochemical interaction 
between USP15 and USP11 may also open to the rational design of allosteric degraders, which 
would have a stronger impact than individually targeted small molecules.  
In summary, we employed an unbiased approach to sensitively and selectively screen for 
DUB function in hematopoietic progenitors in vivo, through which we identified known and 
novel DUB candidates. Major investments are being devoted in the last 5-10 years to DUB drug 
discovery, with more than 40 small molecules against DUBs already developed (Harrigan et al., 
2018; Heideker and Wertz, 2015). Our data strongly argue in favor of developing specific USP15 
inhibitors, which are only starting to emerge. Interestingly, engineered ubiquitin variants 
targeting USP15 have recently been reported (Teyra et al., 2019), which may open up to the 
development of more specific small molecules as well as targeted degraders. More broadly, our 
study calls for a more systematic effort in understanding how DUBs regulate normal and 
malignant HSC biology as a critical route towards the selection of effective drug targets and 
targeted treatment combinations. 
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Figure Legends 
 
Figure 1. Pooled in vivo RNAi screen identifies candidate DUBs effectors of hematopoietic 
stem and progenitors cell activity. 
(A) Overview of the DUB RNAi screens in vivo. Lineage negative (Lin-) cells isolated form wt 
(CD45.2) bone marrow (BM) were grown under stem cell conditions and transduced with pooled 
lentiviral libraries targeting all annotated mouse orthologues of human DUBs (≈100). After 
selection, CD45.2 transduced Lin- cells are mixed 1:1 with CD45.1 support BM cells. A fraction 
of the transduced CD45.2 cells, INPUT (T0), is isolated before injection. Proviral shRNAs 
inserts were sequenced from BM isolated Lin- cells and splenocytes from recipient mice at 4 
weeks post transplantation (wpt) and from INPUT cells to determine the changes in distribution 
of all shRNAs.  
(B) The primary screen was performed with the full shRNA DUB library in five replicate mice. 
The DUB library was divided in two sub-pools, DUB1 and DUB2 sub-libraries, and two 
secondary screens were performed. Most of the targeted genes do not overlap between DUB1 
and DUB2 sub-libraries.   
(C) shRNA library-transduced Lin- cells efficiently engraft and contribute to BM repopulation. 
The Lin- fraction was purified from recipient mice at 4 wpt and analyzed for chimerism. 
Representative FACS profiles are shown.  
(D)  The primary screen shRNAs library complexity is maintained in vivo. Consolidated fraction 
of shRNAs retrieved in vivo in Lin- cells at 4 wpt and in controls. 
(E) Vulcano plot depicting the log2 fold change in the BM of recipient mice of all hairpins used 
in the primary screen, normalized across five replicates.  
(F) Venn diagram depicting significantly differentially represented genes overlapping between 
the primary and secondary screens. Candidate genes were selected with the indicated criteria.  
(G) Vulcano plot depicting the log2 fold change in the BM of recipient mice of all hairpins used 
in the secondary screen (DUB2 sub-library), normalized across seven replicates.  
(E-G) Significantly (AdjPval ≤0.02) dropout (log2 FC≤ 1, blue) and enriched (log2FC ≥1, red) 
shRNAs are highlighted. 
See also Figure S1 and S2. 
 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.23.916627doi: bioRxiv preprint 
 24 
Figure 2. Knockdown of USP15 in hematopoietic stem and progenitor cells reduces their 
proliferation capacity in vitro. 
(A) Overview of the in vitro and in vivo validation assays for USP15-targeting shRNAs. 
(B) Freshly isolated Lin- cells were infected with non-targeting (shScramble) or USP15-targeting 
(shUSP15) shRNAs expressing lentiviruses. The knockdown efficiency of USP15 was detected 
by real-time qPCR using two different pairs of USP15 primers. HPRT was used as the internal 
control for normalization. Mean values of three technical replicates ± SD are shown.  
(C) Flow cytometry analysis of Lin- cells at 1 week post infection with the indicated shRNAs. 
The frequency of LSKs in the Lin-, c-Kit+ population (left panel), and the frequency of Lin-, 
cKit+ and LSK in the live culture (middle and right panel, respectively) was calculated and 
normalized relative to shScramble control. N= 3 independent experiments. Mean values ± SEM 
are shown. FACS representative profiles are presented in Figure S4. 
(D) Freshly purified Lin- cells were plated 7 days post infection with the indicated shRNAs and 
monitored for growth. Kinetic measures the number of cells, recorded over time and plotted as 
phase contrast object confluence. n = 4 wells per data point. Mean values ± SEM are shown. 
For all panels: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. P-value was assessed by Student’s t test 
(A-C) or Multiple t test (D) in Prism 7. See also Figure S3A. 
 
Figure 3. USP15 is required for HSC multilineage reconstitution potential into primary 
recipients.  
Freshly isolated wt murine Lin- cells were transduced with shRNAs targeting USP15 or control 
shRNA and assayed in competitive bone marrow transplantation. 
(A, B) CD45.2 chimerism in peripheral blood (A) and contribution of transduced cells to 
myeloid (Gr1+), B cell (CD19+), and T cell (CD3+) lineages in the blood (B) of recipients at the 
indicated time points. PBC, peripheral blood cells.  
(C) CD45.2 chimerism was measured in B and T cell lineages in the spleen of recipient mice at 
18 wpt.  
(D) Representative FACS profiles of the Lin-, c-Kit+, Sca1+ (LSK) compartment and of 
chimerism analysis of this population in primary recipient mice at 18 wpt.  
(E) CD45.2 chimerism levels in LSK cells in primary recipients (upper panel). Lower panel 
shows the numbers of donor-derived LSK in 106 viable BM cells at 18 wpt.  
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(F) Cell numbers of donor-derived HSC (LSK/CD150+/CD48-) in 106 viable BM cells at 18 wpt.  
(G) Fraction of donor derived progenitors populations (LKS-, CMP, GMP and MEP) in primary 
recipients at 18 wpt.   
Gating strategies and representative FACS profiles are presented in Figure S3. For all panels: *, 
P ≤ 0.05; **, P ≤ 0.01. P-value was assessed by Student’s t test in Prism 7. Data represent mean 
values ± SEM. N=3 per shRNA, except for shUSP15#16, n=4.  
Figure 4.  Reduced hematopoietic stem cell compartment in Usp15 knockout mice. 
(A) Lin-, c-Kit+ cell numbers per million live BM cells. 
(B) LSK cell numbers per million live BM cells.  
(C) HSC (LSK, CD150+, CD48-) cell numbers per million live BM cells.  
(D) Frequency of Lin-, c-Kit+, LSK and HSC in bone marrow of Usp15-/- mice was calculated 
and normalized to Usp15+/+ animals.  
Multiparameter flow cytometry analysis of the hematopoietic primitive populations was 
performed in 8-12 wks old Usp15+/+ and Usp15-/- mice. Gating strategies are presented in 
Figure S3. Results are from three (Lin-, c-Kit+ and LSK; Usp15+/+ n=9, Usp15-/- n=5) or four 
(HSC; Usp15+/+ n=13, Usp15-/- n=7) independent experiments.  
For all panels: *, P ≤ 0.05, ****P ≤ 0.001 as assessed by Student’s t test. n.s.: not significant. 
Error bars represent ± SEM.  
 
Figure 5. Genetic knockout of Usp15 impairs HSC function. 
Competitive transplantation of BM cells freshly isolated from Usp15+/+ or Usp15-/- mice.  
(A, B) Chimerism in peripheral blood (A) and contribution of BM cells to myeloid (Gr1+), B 
cell (CD19+) and T cell (CD3+) lineages in the blood (B) of recipients at the indicated time 
points. PBC, peripheral blood cells.  
(C) Representative FACS profiles (left panels) and numbers of donor-derived LSK per million 
viable BM cells in recipients at 18wpt. 
(D) Representative FACS profiles (left panels) and numbers of donor-derived HSC 
(LSK/CD150+/CD48-) per million viable BM cells in recipients at 18 wpt.  
(E) Numbers of donor-derived myeloid committed progenitor populations (LKS-, CMP, GMP 
and MEP) in recipients at 18 wpt.  
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For all panels: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. P-value was assessed by Student’s t test. 
Error bars represent ± SEM. (A-E): data represent one representative experiment out of 3. 
Recipient mice: (A, B): n=6 for each genotype; (C-E): Usp15+/+ n=4, Usp15-/- n=5.  
(F) Freshly isolated, FACS sorted LSK were plated after 8d (second plating) in culture and 
monitored for growth. Cells were counted at the indicated days and the number of live cells is 
plotted. n = 4 wells per data point. Representative images at day 3 and 8 of the second plating are 
shown. Bar, 20 µm.  
 
Figure 6. USP15 is highly expressed in primary blood-derived cancer. 
(A) Cohort TCGA Pan-Cancer (PANCAN)(total number of samples: 11060) shows up-
regulation of USP15 in Acute Myeloid Leukemia (AML).  
(B) Cohort TCGA PANCAN (11060) shows up-regulation of USP15 in blood-derived tumors.  
(C) USP15 is up-regulated in patients with AML. Log2 transformed expression of USP15 from 
Microarray–Based Gene Expression Profiling of human BM cells (Hemaexplorer). TPM, 
Transcripts Per Kilobase Million. 
(D) High USP15 levels are associated with poor survival. Kaplan-Meier curve correlating 10951 
Pan-cancer patients’ survival with USP15 gene expression is shown. TCGA Pan-Cancer 
(PANCAN) samples used in this analysis are shown in Table S8. 
(E) Expression of USP15 from transcriptional profiling of human cancer cell lines (Cancer Cell 
Line Encyclopedia, Broad Institute) shows up-regulation of USP15 in chronic myeloid leukemia 
(CML) and AML cell lines.  
(F) USP15 normalized expression levels in a panel of leukemia cell lines as assessed by RT-
qPCR (left column) and RNA-seq by CCLE (middle column). The right column indicates the 
relative FAB stage for leukemia subtype classification. 
 
Figure 7. USP15 loss enhances genotoxic stress in human CML leukemic cells and in mouse 
normal hematopoietic progenitors.  
 (A-F) K562 and KBM7 CML cell lines were transfected with USP15 (siUSP15) or non-
targeting (siCtrl) siRNAs and assayed at 72hours after transfection.  
(A) Immunoblotting on whole cell extract with the indicated antibodies.  
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(B) Viability in the indicated cell lines measured at 72 hours after transfection. Mean ± SD from 
three independent experiments is shown. 
(C) Representative images and quantification by Image J of the number of spontaneous 53BP1 
foci per cell. Mean values ± SEM are shown. N=2. A minimum of 250 cells per sample was 
counted over two independent experiments.  
(D) Immunoblotting of USP15-depleted cell lines at 72 hours after transfection. Levels of 
γH2AX and tubulin were assayed.  
(E, F) USP15 depletion significantly increases micronuclei formation in KBM7 (E) and K562 (F) 
cell lines. Quantification and representative images of micronuclei (arrows) are shown. Results 
are mean ± SD from 3 independent experiments. A minimum of 150 (KBM7) or 450 (K562) 
cells was scored.  
(G) Percentage of micronuclei in FACS sorted, murine LSK after 11 d in culture. A minimum of 
60 cells/genotype was scored in two independent experiments (each exp. Usp15+/+ n=3; Usp15-
/- n=2). Mean ± SD is shown. 
(H) KBM7 cells transduced with a doxycycline (dox)-inducible shUSP15 were kept in medium 
with or without dox for 5 days. Cells were then seeded for IR treatment with the indicated dose. 
Cell viability was measured by Alamar Blue 3d after IR. Mean ± SD of two independent 
experiments (each with n=5 replicates per sample) is shown, two-way analysis of variance 
(ANOVA) ****p <0.0001. Similar data were obtained with siUSP15.  
(I) Scatter plot of area under the dose–response curve (AUC) scores indicating sensitivity of 
individual cell lines to either Topotecan or Mitomycin-C. Red dots indicate leukemia cell lines.  
Data are generated by Cancer Target Discovery and Development (CTD2) Network and taken 
from the Cancer Therapeutics Response Portal (CTRP). 
(J) MV4-11 cells harboring USP15 shRNA were kept in medium with or without doxycycline 
(Dox) for 5 days and subsequently plated with the indicated concentration of Mitomycin-C 
(MMC). Western blot (left panel) and cells viability (right panel) were performed at 72 hours of 
MMC treatment. Results are the mean ± SEM of three (-MMC) or two (+MMC) independent 
experiments (each with n=3 replicates per sample). 
For all panels except I: *, P ≤ 0.05, **, P ≤ 0.01, ****, P ≤ 0.0001 as assessed by Student’s t test. 
Panel I: ****p <0.0001 assessed by two-way analysis of variance (ANOVA). Arrows indicate 
micronuclei (MN), nucleoplasmatic bridges (NPB) and nucleoplasmatic bud (NBUD). 
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Materials and Methods 
EXPERIMENTAL MODELS  
Mice: generation and breeding of USP15 knockout mice. Full Usp15 knockout (KO) mice 
(MGI: Usp15<em1Nki>; MGI:5810631; B6J-Usp15<em1Nki>) were generated by CRISPR-
Cas9-mediated deletion of the Usp15 locus in C57BL/6J zygotes as described (Pritchard et al., 
2017). Two CRISPR-guides (gRNAs) were used that target Cas9 mediated double stranded DNA 
cleavage at both the 5’ and 3’ UTR of Usp15. The sequence of the 5’ and 3’ targets were 
TCTTCTTCCACTAGCCGTAGCGG and GTCACTTGATACGATAGCGCCGG, respectively. 
The expected cleavage sites (underlined) are 91.795 bp apart in the C57BL/6J genome (Fig. 
S4A). Mice carrying a full Usp15 knockout (KO) allele, in which the 91 kb of cleavage site 
intermitting sequence is missing, were identified by PCR and sequence analysis. The Usp15 
alleles were detected with the following primers: forward, 5’-TCCAGTAGGAGTGAACCCGC-
3’; reverse KO, 5’-AGGTGGCTGAGAGTGAGAGCAGG-3’; reverse wt, 5’-
GCCTTCCGCCATCTTCTTCCAC-3’, yielding a product of 590 bp and 396 bp for Usp15-KO 
or Usp15 wt, respectively. The predicted CRISPR-Cas9-mediated fusion product for the Usp15-
KO allele is: ccgcta.c.tatcgtat. The 590bp Usp15-KO PCR fragment was sequenced, yielding the 
obtained fusion product: ccgtaTcGGatcgtat. Genotyping was performed by PCR of genomic tail 
DNA using the Extract PCR kit (Bioline, cat. No. BIO-21127). All mice were kept on C57BL/6J 
(The Jackson Laboratory) strain background (CD45.2+) in a specific pathogen-free environment. 
Usp15 mice were maintained heterozygous. All animal experiments comply with Dutch and 
European regulations and ethical guidelines and have been authorized by our local experimental 
animal committee at The Netherlands Cancer Institute (DEC-NKI). For determining survival, 
mice time to death was defined as the latency between birth and unexpected death or a terminal 
disease stage indicated by >20% weight loss or other symptoms of severe sickness. Mice were 
sacrificed by CO2 asphyxiation and underwent necroscopy. Organs were collected and fixed for 
histopathological analysis as described (Lancini et al., 2014).  
 
Cell lines and cell culture. 
 Leukemia cells. KBM7 were grown in IMDM (Gibco) medium. All the other leukemia cell 
lines, including K562 and MV4-11, were grown in RPMI 1640 (Gibco) medium. Culture 
medium was supplemented with 2 mM L-Glutamine (Gibco 25030-164), 10% fetal calf serum 
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(FCS, Thermo Scientific) 100 U ml−1 penicillin, and 100 µg ml−1 streptomycin (Pen/Strep 
Gibco 15140-163). Cells were incubated at 37°C in a humidified atmosphere containing 5% 
CO2.   
U2OS cell line. U2OS osteosarcoma cells were grown in Dulbecco’s modified Eagle medium 
(DMEM; Gibco), supplemented with 10% fetal calf serum (FCS, Thermo Scientific), 100 U 
ml−1 penicillin, and 100 µg ml−1 streptomycin (Pen/Strep Gibco 15140-163). Cells were 
incubated at 37°C in a humidified atmosphere containing 5% CO2. 
 
METHOD DETAILS 
shRNA libraries. Lentiviral hairpins (pLKO.1) targeting annotated DUB genes(Mevissen and 
Komander, 2017) and controls were selected (Table S1). Vectors were individually picked from 
glycerol stocks of The RNAi Consortium library (TRC Mm1.0) (Sigma-Aldrich, MO), grown up 
on agar plates and combined before maxiprep DNA isolation. Pooled plasmid libraries were used 
to produce lentiviral particles using standard procedures (Gargiulo et al., 2014). 
 
In vivo shRNA screens. Lineage negative (Lin-) hematopoietic stem and progenitors cells were 
isolated from the bone marrow (BM) of 8-10 weeks old wild-type (wt) mice (C57BL/6J-
Ly5.2)(CD45.2) and plated in serum-free medium supplemented with cytokines as described 
below. Lin- cells were pre-stimulated for 24 hours (hrs) and transduced with pooled lentiviral 
shRNAs at low multiplicity of infection (MOI <0.5) using spin-inoculation at 1,800 rpm for 90 
min at 32 °C. Twenty-four hours after infection, the cells stably expressing integrated shRNA 
were selected with puromycin (1µg/ml). 48 hours later, cells were harvested, keeping 1 x 106 
cells for DNA extraction of the INPUT(T0) sample. Next, 2x106 Lin- cells for the primary 
screening or 1x106 for the secondary screens (representing a minimum of 3,500-fold enrichment 
over the library), were mixed with 1x106 freshly isolated BM cells from wt (C57Bl/6-
Ly5.1)(CD45.1) mice and injected into recipient mice as described below. Recipient mice were 
sacrificed at 4 weeks post transplantation (wpt) and femurs, tibia, and spleen were collected. Lin- 
cells from BM and CD43-, CD19+, CD220+, CD45.2 splenocytes were purified as described 
below and genomic DNA was extracted for PCR amplification of the shRNAs.  
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PCR and next-generation sequencing. shRNAs sequences were retrieved from genomic DNA 
by PCR amplification as described (Gargiulo et al., 2014). For every sample, a maximum of 8 µg 
genomic DNA was divided over 4 50-µl PCR reactions using barcoded forward primers (PCR1). 
The products of all reactions were pooled and a maximum of 1 µg from this PCR1 was used per 
reaction in subsequent PCR2 reactions using primers containing Indexes for next generation 
sequencing. Barcodes and Indexes for deep sequencing (Illumina HiSeq 2000) were incorporated 
into PCR primers as listed in Table S4. 
PCR mixture per reaction: 10 µl HF Buffer (NEB), 1.25 µl 10-µM forward primer, 1.25 µl 10-
µM reverse primer, 1.25 µl Phusion Hot Start II polymerase (2U µl-1; Thermo Scientific, cat.n. F-
530L), 1 µl 10-mM dNTPs, DMSO 3% (vol/vol), adding mQ and template to 50 µl. PCR 
conditions were: 1’ @ 98 °C, 16 (PCR1) or 14 (PCR2) x (10s @ 98 °C, 30s @60 °C,  60s @ 72 
°C), 5 min @ 72 °C. PCR products were purified using the AMPure XP solid-phase reversible 
immobilization kit (SPRI; Beckman Coulter, cat. no. A63881) and subjected to Illumina next-
generation sequencing. The shRNA sequence reads were aligned to the TRC library. Fold change 
in individual hairpin representation in vivo was determined by comparing shRNA representation 
in each sample to that in the control cell population remaining after tail vein injections during 
bone marrow transplantation (INPUT, T0). Each condition included in the preliminary analysis 
was matched to its corresponding shRNA library removing those shRNA that weren’t present in 
any of the samples. Pairwise differential abundance analysis was performed between test sample 
and input using limma v3.36 (Ritchie et al., 2015) after outlier removal using PCA. shRNA were 
considered as enriched or dropped out if logFC was higher than |1|, adj.Pvalue  <= 0.02 and avg. 
abundance > 2.5 .  The analysis was done using R v3.5 programming language (https://cran.r-
project.org/).  
 
Bone marrow transplantation assays. For RNAi in vivo screens, puromycin selected, 
retroviral-transduced Lin- cells (CD45.2) were mixed with wt bone marrow cells (CD45.1) as 
described above and injected into lethally irradiated (2 doses of 5.5 Gy TBI separated by an 
interval of 3 hours) wt C57BL/6-CD45.1 recipient mice. Donor contribution was assessed based 
on the expression of CD45.1/CD45.2 antigens. At 4 wpt primary recipients were sacrificed and 
the frequency of donor-derived CD45.2 peripheral blood cells, splenocytes, Lin- and LSK were 
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assayed by phenotypic profiling. Lin- cells and CD45.2 splenic B cells for genomic DNA 
extraction and shRNA retrieval were isolated as described below.  
In validation experiments, wt Lin- cells were transduced with individual lentiviral vectors 
and puromycin-selected as indicated above. 1x106 lentiviral-transduced, puromycin resistant 
cells (CD45.2) were transplanted together with 1x106 total BM cells (CD45.1) into lethally 
irradiated recipient mice (CD45.1). Recipient mice peripheral blood was monitored by FACS 
analysis at 2 wpt and every 4 wk for 18 wk. Donor contribution and multilineage reconstitution 
were assessed based on the expression, respectively, of CD45.1/CD45.2 antigens or CD19, CD3, 
and Gr1 markers in the CD45.2+ fraction. At 18 wpt, primary recipients were sacrificed and the 
frequency of donor-derived CD45.2 B and T cells in the spleen and Lin-, LSK, HSC and myeloid 
progenitors in the bone marrow was assayed by phenotypic profiling.  
In competitive BM transplantation, BM was isolated from donor test animals (CD45.2, 
Usp15+/+ or Usp15-/-) and mixed in a 1:1 ratio with wt competitor cells (CD45.1)(8-10 weeks 
old mice). For each genotype and for the wt competitor BM, cells from 3 donors and from 3 wt 
competitor mice were isolated and pooled before 1:1 mixing. Thereafter, 1 × 106 CD45.1/CD5.2 
mixed BM cells were transplanted into lethally irradiated CD45.1 recipient mice as described 
above. Flow cytometry staining for LSK and HSC of donors was performed to ensure that the 
HSC frequency in test and control BM would be comparable. Differences in HSC were corrected 
before transplantation to transplant stem cell equivalents. Chimerism in the blood of primary 
recipients and BM repopulation at 18 wpt were assessed as described above.  
Mice were irradiated using Faxitron MultiRad 225 X-ray irradiation system. Irradiated mice 
were treated with Enrobactin for the first 4 wk after irradiation. Immunophenotyping, Lin- 
isolation and CD45.2 splenocytes purification were performed as described below.  
 
Flow cytometry 
Blood. Peripheral blood was collected into EDTA-coated micro-tubes. For FACS analysis, blood 
was depleted from red blood cells by hypotonic lysis and staining was performed with 
fluorochrome-labelled antibodies, CD3-FITC, CD11b-PerCp/Cy5.5, CD19-APC, Gr1-APC/Cy7.  
Spleen. Single cell suspension of spleen was obtained by smashing through a 70µm filter. 
Suspension was depleted from red blood cells by hypotonic lysis. For isolation of immature and 
of mature (resting) B cells, CD43 positive cells were first depleted using anti-mouse CD43 (Ly-
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48) MicroBeads (MACS Miltenyi Biotec). Donor derived cells were then isolated by FACS 
sorting using fluorochrome-labelled antibodies CD45.2-FITC, CD45.1-PE, CD19-APC, B220-
Pb, CD43-biotin and Streptavidin APC/Cy7. For immunophenotyping of spleen upon 
transplantation, staining was performed with fluorochrome-labelled antibodies, CD3-FITC, 
CD8a-PerCp/Cy5.5, CD4-APC, CD19-APCH7.  
Analyses and cell sorting of hematopoietic precursors. To analyze Lin-, LSK, HSC, LKS-, 
CMP, GMP and MPP subpopulations (Cabezas-Wallscheid et al., 2014; Kiel et al., 2005; Oguro 
et al., 2013; Wilson et al., 2008; Yeung and Wai Eric So, 2009), BM freshly isolated 
mononuclear cells (MNC) were first stained with Lineage Cell Detection Cocktail-Biotinylated 
mouse antibody (MACS Miltenyi Biotec). For FACS analysis, cells were then directly stained 
with fluorochrome-conjugated antibodies. We used 5 x 106 MNCs per staining. For quantifying 
LSK and HSC populations, cKit-APC, Sca-1-PerCp/Cy5.5, CD48-FITC, CD150-PE/Cy7, 
CD135-PE and streptavidin-APC/Cy7 antibodies were used. For quantifying LKS- progenitor 
populations, cKit-APC, Sca-1-PerCp/Cy5.5, CD34-FITC, CD16/32-PECy7, and streptavidin-
APC/Cy7 antibodies were used. For purifying Lin- cells for shRNA library viral infection or for 
culturing, depletion of lineage+ cells from MNCs was performed using Biotin labeled Lin+ 
cocktail and Streptavidin MicroBeads (Macs; Miltenyi Bio- tec) and magnetic columns (Macs; 
Miltenyi Biotec). For cell sorting of LSK, depletion of lineage+ cells was first performed as 
above before staining.  
Cell cycle analysis of BM populations. Cell surface staining was performed as described above. 
Samples were then fixated in 3.7% Formaldehyde in PBS (Sigma)) for 30 min at RT. Cells were 
permeabilised in PBS/BSA(1%)/Tween20 (0.025%)(PBT) for 15min at RT and harvested in PBT 
containing 10 µg/mL DAPI for chromatin labeling. Cell cycle analysis was performed as 
described (Pilzecker et al., 2017).  
Assessing Cleaved Caspase-3 levels of BM populations. Cell surface staining, fixation and 
permeabilization was performed as described above followed by staining with Cleaved Caspase-
3-AF488 antibody for 30 min at RT in PBT. Cells were washed twice with PBT and harvested in 
PBT containing 10 µg/mL DAPI for chromatin labeling. 
All FACS measurements were performed with a BD LSRFortessa cell analyzer (BD 
Biosciences). Cell sorting was performed with a FACSAria (BD). All FACS data were analyzed 
using FlowJo Software version 10.0.8r1. (Tree Star).  
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Hematopoietic stem and progenitor cells liquid culture, time-lapse imaging and 
proliferation assays. Mice were sacrificed at the indicated age (8-12 weeks). Lineage negative 
(Lin-) isolation, LSK FACS sorting and cell surface staining was performed as described above. 
Cells were plated on Ultra-Low Attachment multiwell plates (Corning®Costar®) in StemPan 
SFEM (StemSpan™ Serum-Free Expansion Medium (SFEM) STEMCELL Technologies) 
supplemented with mouse SCF 100 ng/ml, mouse thrombopoietin (mTpo) 50 ng/ml and mFlt3 
ligand 50 ng/ml (PrepoTech)(Ye et al., 2008). Medium was replenished and cells were expanded 
in 3% oxygen to maintain optimal growth. To evaluate proliferation, 1,000 Lin- cells were plated 
in 96-well plates at day 7 of culture. 4 wells per conditions were imaged (phase-contrast) with a 
4 hrs interval for 6.5 d using the IncuCyte FRL (Essen BioScience). Confluence was determined 
by the IncuCyte software, based on area (confluence) metrics. Plating of 500 cells/well gave 
similar results. FACS sorted LSK cells from individual animals were grown individually. LSK 
were plated at day 8 of culture and monitored for growth by counting live cells by Trypan blue 
exclusion using a TC20TM Automated Cell Couter (BIORAD) at the indicated time. Four wells 
per condition were counted. 
 
CFU-C colony-forming assay. BM MNCs cells were seeded on 35-mm culture dishes in 
triplicate in methylcellulose medium supplemented with cytokines (MethoCult GF M3434, 
STEMCELL Technologies). CFU-Cs (colony forming units in culture) include CFU-GEMM 
(granulocyte, erythroid, macrophage, megakaryocyte), multipotential progenitors and lineage-
restricted progenitors of the erythroid (BFU-E, burst-forming unit–erythroid), and granulocytic, 
monocyte- macrophage (CFU-GM). Cultures were incubated at 37°C under 5% CO2. Colonies 
were quantified at day 8.  
 
Leukemia cells RNA interference and cell viability assays. USP15 siRNAs (siGENOME 
Human USP15 (9958) siRNA-SMART pool M-006066-01) and control (Ctrl) siRNAs 
(siGENOME Non-Targeting siRNA Control Pool#2 D-001206-14-05) were from Dharmacon. 
Cells were transfected using Lipofectamine® RNAiMAX Reagent from Life Technologies 
following the manufacturer’s instructions and assayed at 72 hrs after transfection in Western 
blotting, viability assays and immunofluorescence or RNA-seq.  
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For inducible USP15 knockdown experiments, we have tested 4 shRNAs. To rule out potential 
off-target effects by one shRNA, we used two different shRNAs for experiments in Figure 7H-J  
(sequences ‘TAAACCAGCATCCTGAATGG’ and ‘TTTCATGAACTCAGCTATTC’, 
respectively). The additional shRNA tested were: ‘GCATTAGGCTGCCGTATATA’, and 
‘CGCTTATAAGAACTATGATT’ and these were found insufficiently potent on-target. The 
shRNA-containing bicistronic vectors were either subcloned in synthetized at VectorBuilder, and 
included a H1 promoter and Tet operator shRNA cassette as well as a Tet repressor-T2A-eGFP 
for FACS sorting of TetR positive cells. 
Viability assays were performed using AlamarBlueTM Cell Viability reagent (Thermo Fisher 
Scientific). Relative viability was normalized to the control siRNA transfected cells and 
corrected for back-ground signal. 
 
TCGA pan-cancer gene expression analysis. Gene expression analysis by RNAseq was 
compiled using data from all TCGA cohorts. Gene expression was measured using the 
IlluminaHiSeq technology. Data from all TCGA cohorts are combined to produce this dataset. 
Values are PANCAN expression unit - (log(norm(exp) + 1)) transformed RSEM values.  
 
RNA-seq gene expression analysis. For gene expression analysis, KBM7 or K562 cells were 
transfected with USP15 or control siRNAs as described above. Total RNA was extracted at 72 h 
after transfection. For LSKs, cells were FACS sorted from freshly isolated BM and total RNA 
was extracted. n=3 Usp15+/+ and n=2 Usp15-/- littermates (2 months old). Samples were 
prepared using TruSeq protocols, and standard sample preparation protocols and RNA-seq was 
performed on a Hiseq2000 machine (Illumina) at the NKI Genomics Core Facility.  
The data discussed in this publication will be available from the NCBI’s Gene Expression 
Omnibus database (Edgar et al., 2002). 
 
Sensitivity assays. Cells were cultured in the proper culture medium with doxycycline for 5 days 
(100ng/ml) to induce USP15 knockdown. Cells were then seeded in 384 well plates 24 hrs before 
treatment. For IR, cells were irradiated with the indicated dose and cell viability was assessed 3 
days after IR using a medical irradiator platform (XenX). To determine the 30nM MMC 
concentration, MMC dose-response experiments were previously assessed and 30nM was 
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determined as the IC50 dose for MV4-11 cells in our experimental conditions. Cell viability was 
assessed at 72 hours. Doxycycline and drug were refreshed daily. 
In vivo cisplatin (CsPt) Sensitivity Assay. Mice were injected i.v. with 0.8 mg/kg cisplatin 
or PBS. After 2 d, the BM was isolated and analyzed as described above. 
 
Immunofluorescence and quantitative image analysis. In vitro cultured murine LSK or human 
K562 and KBM7 cells were deposited on charged slides (Superfrost Plus; Menzel-Glaser) by 
cytospin and directly fixed in 4% paraformaldehyde. Immunostaining with antibodies against 
53BP1 was performed as previously described (Lancini et al., 2014). Counterstain was with 
Alexa Fluor 488–conjugated secondary antibodies and DAPI (200 ng/ml) (Sigma-Aldrich). 
Micronuclei were scored on fixed cells stained with DAPI. Digital images were acquired using a 
microscope (AxioObserver Z1; Carl Zeiss) with an ORCA-ER CCD charge-coupled device) 
camera (C4742-80-12AG; Hamamatsu) and Zen software (40x and 63x magnification). A macro 
in ImageJ software (version:2.0) (developed by Bram van den Broek, NKI, Amsterdam) was 
used for quantification of spontaneous 53BP1 DNA damage foci. The DAPI channel was used to 
select the nuclei of the cells in the field. Briefly, Z-stacks are converted to two dimensional via 
one of several user-defined methods: maximum intensity projection, automatically select 
sharpest slice or manually select a slice. Region of interests (ROIs) of candidate nuclei are then 
automatically obtained throughout the image stack by auto-thresholding an outlier-removed 
median-filtered (0.7 mm radius) z projection of the nuclei channel, followed by a watershed 
command to separate touching nuclei and particle analyser run with size (>4 and 40 µm2), and 
circularity (>0.25) constraints. In the detection of 53BP1 foci, the foci threshold level is defined 
by the signal-to-noise ratio (SNR): a (user-set) factor times the s.d. of the background 
fluorescence intensity of the nucleus. The latter property is approximated by first crudely 
removing signal outliers (the foci), and then taking the median and s.d. of the lower approximate 
80% pixel values in the ROI, respectively. The background intensity is subtracted using a 
Difference of Gaussians filter. Foci are then identified as regions of adjacent pixels with grey 
values, exceeding the SNR threshold and area larger than a certain minimum. In the procedure, 
the SNR is the only user-defined parameter, and is iteratively optimized by comparing the 
detected foci with the original signal in an overlay image.  
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Protein analysis. Cell were lysed with RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% 
Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM PMSF) containing 
protease inhibitor cocktail (Complete, Roche) and phosphatase inhibitors 9Na Fluoreide 10mM 
final concentration, Na orthovanadate 1 mM final concentration and NaPPi 1 mM final 
concentration) and whole cell extract was loaded on SDS-PAGE on NuPAGE gels, followed by 
Western blotting with the indicated antibodies (Table S4). Filter blocking and antibody 
incubation were performed in PBS supplemented with 0.1(v/v) % Tween and 5%(w/v) bovine 
milk powder.  
 
Quantitative real-time (qRT) PCR. Total RNA was extracted using TRIZOL reagent (Life 
Technologies) or ReliaPrepTM RNA miniprep System (Promega) and cDNA was prepared using 
Superscript II RT and oligo(dT)n primers (Life technologies). qRT-PCR was performed on a 
StepOnePlusRT-PCRsystem(AppliedBiosystems) usingSYBR Green PCR Master Mix (Applied 
Biosystems). The amount of target, normalized to an endogenous reference (HPRT), was 
calculated by 2-ΔΔCT. Primer sequences were as follows: Hprt forward, 5’-
CTGGTGAAAGGACCTCTCG-3’; Hprt reverse, 5’-
TGAAGTACTCATTATAGTCAAGGGCA-3’; Usp15 forward A, 5’- 
TGTGGCTTAAGTAACTTGGGAAA-3’; Usp15 reverse A 5’-
AAGTGGAGGTGTGTTGCTCA-3’; Usp15 forward B, 5’-TCAGCTGGTACACACTGATGG-
3; Usp15 reverse B, 5’-TGCTTTACAAACATACCCTGTTCT-3’. 
Primers used in Fig. S5G,H for validation of RNA-seq results are available upon request. 
 
Antibodies. Antibody specifications are listed in Table S5 and S6. 
 
sgRNA design and cloning. 
sgRNA sequences targeting human USP15 were selected from the Human Brunello CRISPR 
knockout pooled library (Doench et al., 2016)(Addgene #73178) and further selected on the basis 
of high quality score in two additional online tools: CRISPR Design (http://crispr.mit.edu/) and 
CRISPRscan (http://www.crisprscan.org/). The following sgRNA (sg01) targeting exon 3 of 
USP15 DUSP domain was used in this study: USP15ex3, 5’-AAGGTGTTCCTTAAGTGACT-
3’. Pairs of complementary DNA oligos (for: 5’-caccgAAGGTGTTCCTTAAGTGACT-3’; rev: 
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5’-aaacAGTCACTTAAGGAACACCTTc-3’) were annealed and the DNA oligonucleotide 
duplex was cloned in the Bbs1 restriction site of pSpCas9(BB)-2A-GFP (PX458) plasmid 
(Plasmid #48138, Addgene). sgRNA sequence was verified by DNA Sanger sequencing using 
the following primer: ASK-FN2 5'-CGGCCTTTTTACGGTTCCTG-3'. 
 
Transfection and fluorescence activated cell sorting (FACS). Plasmids were transfected into 
U2OS cells using FuGENE® HD Transfection Reagent (Promega), according to the 
manufacture’s instructions. After 48 hours in culture, cells were trypsinized, washed with PBS, 
and resuspended in PBS (supplemented with 3% BSA) and passed through a cell strainer 
(Falcon® Round-Bottom Tubes with Cell Strainer Cap, Catalog #38030). Cells were 
individually sorted (BD FACSAria, BD FACS Diva 8.0.1 sofware) based on EGFP signal into 
tissue culture 96-well plates (CELLSTAR-Greiner) at a single cell per well for clonal expansion. 
Viable individual clones were then transferred to 24 well plates for clonal expansion and 
screening.  
 
Genomic DNA extraction, PCR and Sanger sequencing and TIDE analysis 
Genomic DNA was extracted using DNeasy Blood & Tissue Kit (QIAGEN). The genomic 
region around the gRNA-targeted sequence was amplified using the following primers: for,5’- 
GTTAGTGTTACAATTCTTCCAATACGG-3’; 
rev,5’GTTTTATCAAAAACAGTGCAGCACAG-3’. PCR was performed using Thermo 
Scientific® Phusion High-Fidelity DNA polymerase in GC buffer. PCR conditions were as 
follows: 30s at 95°C, followed by 325 cycles of 30s at 95 °C, 30s at 64 °C, and 30s at 72 °C, 
followed by 3 min at 72 °C. Primer 5’-TTACAATTCTTCCAATACGGCCCAG-3’ was used for 
Sanger sequencing. About 100-200 ng DNA from purified PCR samples was prepared for 
sequencing using BigDye terminator v3.1. Samples were analyzed by an Applied Bio- systems 
3730x1 DNA Analyzer. The data obtained was analyzed using the TIDE software 
(https://tide.nki.nl). The decomposition window used for TIDE was set to indels of size 0-10 bp, 
p threshold of 0.001.   
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QUANTIFICATION AND STATISTISAL ANALYSIS 
Statistical analysis was performed in GraphPad Prism 7.0, using an unpaired two-tailed Student’s 
t test or Multiple t test. Animal survival experiments were analyzed with a Log-rank 
nonparametric test and expressed as Kaplan-Meier survival curves. In all Fig.s: *, P <0.05; **, P 
< 0.01; ***, P < 0.001; ****, P < 0.0001. 
 
DATA AND CODE AVAILABILITY 
The RNA-sequencing data discussed in this publication will be available from the NCBI’s Gene 
Expression Omnibus database (Edgar et al., 2002). 
 
Supplemental Information 
Supplemental Figures 
Figure S1 (relative to Figure 1). In vivo RNAi screens for DUBs in murine hematopoietic stem 
and progenitor cells.  
Figure S2 (relative to Figure 1). Pooled in vivo RNAi screens identify candidates DUBs effectors 
of HSC activity.  
Figure S3 (relative to Figures 2C, 3, 4 and 5). Flow cytometry and gating strategies. 
Figure S4. Generation and initial characterization of Usp15 knockout mouse model (relative to 
Figure 4).   
Figure S5. USP15 RNAi in CML cell lines results in alteration of inflammatory signaling 
pathways.  
Figure S6. USP15 loss enhances genotoxic stress in vitro in human cancer cells and in vivo in 
mouse hematopoietic stem and progenitor cells. 
 
Supplemental Tables 
Table S1 (relative to Figure 1). Genes targeted and shRNAs used in the primary and secondary in 
vivo screens. 
Table S2 (relative to Figure 1).  DUBs tested in the primary and secondary in vivo screens. 
Table S3 (relative to Figure 1). Results from in vivo RNAi screens. 
Table S4. Primer sequences for Illumina sequencing multiplexing strategy. 
Table S5. Hematopoietic stem and progenitor cell populations and their markers. 
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Table S6. List of antibodies used in this study. 
Table S7 (relative to Figure S4). Inflammation in Usp15-/- mice. 
Table S8 (relative to Figures 6A, B and D). TCGA Pan-Cancer (PANCAN) samples.
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Figure 6. USP15 is highly expressed in primary blood-derived cancer.
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Figure 7. USP15 loss enhances genotoxic stress in human CML leukemic cells and in mouse normal
 hematopoietic progenitors.   
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